NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers

用于治疗腹膜转移性卵巢癌的近红外激活前药

基本信息

  • 批准号:
    9207769
  • 负责人:
  • 金额:
    $ 30.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-03-01 至 2020-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Ovarian cancer (estimated 21,980 new cases and 14,270 deaths in 2014) is the most lethal gynecologic malignancy, and is often discovered in advanced stages when the cancer has metastasized to the peritoneal cavity. Effective eradication of remaining cancers, after optimal debulking surgery, is the key to successful treatment of peritoneally metastasized ovarian cancers. However, current standard treatment (chemotherapy following the surgery) has failed to greatly improve overall survival rates and still causes systemic side effects. Thus, a more effective and safe treatment regimen is urgently needed. This proposal addresses these issues with a unique multifunctional prodrug strategy. Our long-term goal is to develop a platform multifunctional prodrug strategy to achieve synergistic combination of site-specific chemotherapy and photodynamic therapy (PDT, an FDA-approved photochemistry-based regime), which maximizes therapeutic efficacy and minimizes side effects. It is also applicable to a wide range of metastatic tumors. Each prodrug is comprised of an anticancer drug, singlet oxygen (SO)-labile linker, a fluorescent photosensitizer, and cancer- targeting group. Once illuminated by visible-NIR light, the prodrug generates SO that directly damages cancer cells and tumor vasculature (PDT effects). It also releases active drugs only in tumors. PDT is mechanistically distinct from chemotherapeutic drugs and also effectively kills chemo-resistant cancer cells. Thus, the combination of PDT and chemotherapy will provide maximum efficacy. Side effects are avoided by site-specifically releasing drugs only in tumors following specific delivery of inactive prodrugs to tumors. To actively and externally control the release of drug by visible-NIR, we use our novel SO-labile linker. We also employ physiological synergistic effects to minimize the diffusion of the site-specifically released drugs to the systemic circulation. Both vascular damage by PDT and tight binding of drugs to their targets limit the diffusion of the drugs from tumor to blood circulation, avoiding systemic side effects of the drugs. The goals will be realized with 3 specific aims: (1) Synthesize, optimize, and evaluate targeted prodrugs of chemotherapeutic agents, (2) Validate the physiologically-based pharmacokinetic (PK) model and mechanisms of tumor damage, (3) Determine tumor-detection efficiency and antitumor effects for peritoneal ovarian tumors. Major deliverables of this proposal will be (i) targeted prodrugs optimized for ovarian cancers, (ii) physiology-based PK models of prodrugs, which can be a foundation for models of future prodrugs, and (iii) validation of applicability of our prodrugs for optical detection and treatment for orthotopic mouse models with metastasized peritoneal ovarian cancers. The findings of this proposal will significant impact outcomes for patients with metastasized resistant and advanced (stages II-IV) ovarian cancers. The strategy of this proposal will also be adaptable to a wide array of metastatic tumors. The platform prodrugs will also impact scientific research by providing novel and effective prodrug strategy for spatio-temporal drug delivery tools.
 描述(申请人提供):卵巢癌(2014年估计有21,980例新病例和14,270例死亡)是最致命的妇科恶性肿瘤,通常在癌症已经转移到腹膜腔的晚期被发现。腹膜转移性卵巢癌的成功治疗的关键是在最佳去瘤手术后有效地根除残留的肿瘤。然而,目前的标准治疗(手术后化疗)未能显著提高总体存活率,仍然 会引起全身副作用。因此,迫切需要一种更有效、更安全的治疗方案。这项提案通过一种独特的多功能前药战略解决了这些问题。我们的长期目标是开发一种平台多功能前药战略,以实现定点化疗和光动力疗法(PDT,FDA批准的基于光化学的疗法)的协同组合,从而最大化治疗效果并将副作用降至最低。它也适用于多种转移性肿瘤。每种前药由抗癌药物、单线态氧(SO)不稳定连接体、荧光光敏剂和癌症靶向基团组成。一旦被可见光-近红外光照射,前药就会产生,从而直接损害癌细胞和肿瘤血管系统(PDT效应)。它还只在肿瘤中释放活性药物。PDT在机制上与化疗药物不同,也能有效地杀死耐药癌细胞。因此,光动力疗法和化疗的结合将提供最大的疗效。通过将非活性前体药物特定地递送到肿瘤后,仅在肿瘤中定位释放药物,可以避免副作用。为了通过可见-近红外光谱主动和外部控制药物的释放,我们使用了我们的新型不稳定的连接物。我们还利用生理协同效应来最大限度地减少特定部位释放的药物扩散到体循环。PDT造成的血管损伤和药物与靶点的紧密结合都限制了药物从肿瘤向血液循环的扩散, 避免药物的全身副作用。这些目标的实现有三个具体目标:(1)合成、优化和评价靶向化疗药物;(2)验证基于生理的药代动力学(PK)模型和肿瘤损伤机制;(3)确定腹膜卵巢肿瘤的肿瘤检测效率和抗肿瘤效果。这项建议的主要成果将是:(I)针对卵巢癌优化的靶向前体药物,(Ii)基于生理学的前体药物PK模型,它可以作为未来前体药物模型的基础,以及(Iii)验证我们的前体药物在光学检测和治疗方面的适用性 用于腹膜卵巢癌转移的原位小鼠模型。这项建议的结果将对转移性、耐药和晚期(II-IV期)卵巢癌患者的预后产生重大影响。这项提议的策略也将适用于广泛的转移性肿瘤。前药平台还将通过为时空给药工具提供新颖有效的前药策略,对科学研究产生影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Youngjae You其他文献

Youngjae You的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Youngjae You', 18)}}的其他基金

Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers
用于治疗非肌肉侵袭性膀胱癌的单线态氧可裂解前药
  • 批准号:
    10665068
  • 财政年份:
    2022
  • 资助金额:
    $ 30.34万
  • 项目类别:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
用于治疗腹膜转移性卵巢癌的近红外激活前药
  • 批准号:
    10056534
  • 财政年份:
    2015
  • 资助金额:
    $ 30.34万
  • 项目类别:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
用于治疗腹膜转移性卵巢癌的近红外激活前药
  • 批准号:
    9263824
  • 财政年份:
    2015
  • 资助金额:
    $ 30.34万
  • 项目类别:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
用于治疗腹膜转移性卵巢癌的近红外激活前药
  • 批准号:
    9023578
  • 财政年份:
    2015
  • 资助金额:
    $ 30.34万
  • 项目类别:
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
使用光响应缀合物进行光生物调节的位点特异性药物递送
  • 批准号:
    10735978
  • 财政年份:
    2015
  • 资助金额:
    $ 30.34万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 30.34万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 30.34万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 30.34万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 30.34万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 30.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了